Compare BridgeBio Pharma Inc (BBIO) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Live Nation Entertainment, Inc. — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while Live Nation Entertainment, Inc. trades at $180.84 (market cap $42.25B). The key difference: Live Nation Entertainment, Inc. is far larger — about 2.6× BridgeBio Pharma Inc's market cap. Which is the better fit depends on your goals.
| BBIO | LYV | |
|---|---|---|
Market Cap | $16.46B | $42.25B |
Sector | Health | Industrials |
52-Week High | $90.17 | $186.59 |
52-Week Low | $44.81 | $125.61 |
Enterprise Value | $18.02B | $43.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Live Nation (LYV) trades at $183.25, up 1.92% with strong analyst support (88.6% buy ratings) and a $200.20 consensus target. The stock shows bullish technical signals with support at $178 and resistance at $185. Despite recent earnings misses, revenue grew to $25.2B in 2025, though net margins remain thin at 0.33% with negative ROE of -24.68%.
The outlook remains positive given strong concert demand and ticketing dominance, but elevated valuation (P/E 117.5) and regulatory scrutiny pose risks. Cash flow improved to $1.0B net in 2025, supporting growth investments. Institutional sentiment favors upside to price targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
